Cargando…
Vaccination against type 1 angiotensin receptor prevents streptozotocin-induced diabetic nephropathy
ABSTRACT: Recently, our group has developed a therapeutic hypertensive vaccine against angiotensin (Ang) II type 1 receptor (AT1R) named ATRQβ-001. To explore its potential effectiveness on streptozotocin-induced diabetic nephropathy, male Sprague Dawley rats were randomly divided into two groups: a...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4762923/ https://www.ncbi.nlm.nih.gov/pubmed/26407577 http://dx.doi.org/10.1007/s00109-015-1343-6 |
_version_ | 1782417165052280832 |
---|---|
author | Ding, Dan Du, Yimei Qiu, Zhihua Yan, Sen Chen, Fen Wang, Min Yang, Shijun Zhou, Yanzhao Hu, Xiajun Deng, Yihuan Wang, Shijia Wang, Liangping Zhang, Hongrong Wu, Hailang Yu, Xian Zhou, Zihua Liao, Yuhua Chen, Xiao |
author_facet | Ding, Dan Du, Yimei Qiu, Zhihua Yan, Sen Chen, Fen Wang, Min Yang, Shijun Zhou, Yanzhao Hu, Xiajun Deng, Yihuan Wang, Shijia Wang, Liangping Zhang, Hongrong Wu, Hailang Yu, Xian Zhou, Zihua Liao, Yuhua Chen, Xiao |
author_sort | Ding, Dan |
collection | PubMed |
description | ABSTRACT: Recently, our group has developed a therapeutic hypertensive vaccine against angiotensin (Ang) II type 1 receptor (AT1R) named ATRQβ-001. To explore its potential effectiveness on streptozotocin-induced diabetic nephropathy, male Sprague Dawley rats were randomly divided into two groups: a control and a diabetic model. After 1 week, the diabetic rats were divided into four subgroups (each with 15 rats) for 14-week treatments with saline, olmesartan, ATRQβ-001, and Qβ virus-like particle (VLP), respectively. In addition to lower blood pressure, ATRQβ-001 vaccination ameliorated biochemical parameter changes of renal dysfunction, mesangial expansion, and fibrosis through inhibiting oxidative stress, macrophage infiltration, and proinflammatory factor expression. Furthermore, ATRQβ-001 vaccination suppressed renal Ang II-AT1R activation and abrogated the downregulation of angiotensin-converting enzyme 2-Ang (1–7), similar to olmesartan treatment, while no obvious feedback activation of circulating or local renin-angiotensin system (RAS) was only observed in vaccine group. In rat mesangial cells, the anti-ATR-001 antibody inhibited high glucose-induced transforming growth factor-β1 (TGF)-β1/Smad3 signal pathway. Additionally, no significant immune-mediated damage was detected in vaccinated animals. In conclusion, the ATRQβ-001 vaccine ameliorated streptozotocin-induced diabetic renal injury via modulating two RAS axes and inhibiting TGF-β1/Smad3 signal pathway, providing a novel, safe, and promising method to treat diabetic nephropathy. KEY MESSAGES: Overactivation of RAS plays a crucial role in the development of the DN. Our aim was to verify the effectiveness of ATRQβ-001 vaccine in STZ-induced DN. The ATRQβ-001 modulated two RAS axes and inhibited TGF-β1/Smad3 signal pathway. The vaccine therapy may provide a novel, safe, and promising method to treat DN. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00109-015-1343-6) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4762923 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-47629232016-03-03 Vaccination against type 1 angiotensin receptor prevents streptozotocin-induced diabetic nephropathy Ding, Dan Du, Yimei Qiu, Zhihua Yan, Sen Chen, Fen Wang, Min Yang, Shijun Zhou, Yanzhao Hu, Xiajun Deng, Yihuan Wang, Shijia Wang, Liangping Zhang, Hongrong Wu, Hailang Yu, Xian Zhou, Zihua Liao, Yuhua Chen, Xiao J Mol Med (Berl) Original Article ABSTRACT: Recently, our group has developed a therapeutic hypertensive vaccine against angiotensin (Ang) II type 1 receptor (AT1R) named ATRQβ-001. To explore its potential effectiveness on streptozotocin-induced diabetic nephropathy, male Sprague Dawley rats were randomly divided into two groups: a control and a diabetic model. After 1 week, the diabetic rats were divided into four subgroups (each with 15 rats) for 14-week treatments with saline, olmesartan, ATRQβ-001, and Qβ virus-like particle (VLP), respectively. In addition to lower blood pressure, ATRQβ-001 vaccination ameliorated biochemical parameter changes of renal dysfunction, mesangial expansion, and fibrosis through inhibiting oxidative stress, macrophage infiltration, and proinflammatory factor expression. Furthermore, ATRQβ-001 vaccination suppressed renal Ang II-AT1R activation and abrogated the downregulation of angiotensin-converting enzyme 2-Ang (1–7), similar to olmesartan treatment, while no obvious feedback activation of circulating or local renin-angiotensin system (RAS) was only observed in vaccine group. In rat mesangial cells, the anti-ATR-001 antibody inhibited high glucose-induced transforming growth factor-β1 (TGF)-β1/Smad3 signal pathway. Additionally, no significant immune-mediated damage was detected in vaccinated animals. In conclusion, the ATRQβ-001 vaccine ameliorated streptozotocin-induced diabetic renal injury via modulating two RAS axes and inhibiting TGF-β1/Smad3 signal pathway, providing a novel, safe, and promising method to treat diabetic nephropathy. KEY MESSAGES: Overactivation of RAS plays a crucial role in the development of the DN. Our aim was to verify the effectiveness of ATRQβ-001 vaccine in STZ-induced DN. The ATRQβ-001 modulated two RAS axes and inhibited TGF-β1/Smad3 signal pathway. The vaccine therapy may provide a novel, safe, and promising method to treat DN. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00109-015-1343-6) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2015-09-26 2016 /pmc/articles/PMC4762923/ /pubmed/26407577 http://dx.doi.org/10.1007/s00109-015-1343-6 Text en © The Author(s) 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Ding, Dan Du, Yimei Qiu, Zhihua Yan, Sen Chen, Fen Wang, Min Yang, Shijun Zhou, Yanzhao Hu, Xiajun Deng, Yihuan Wang, Shijia Wang, Liangping Zhang, Hongrong Wu, Hailang Yu, Xian Zhou, Zihua Liao, Yuhua Chen, Xiao Vaccination against type 1 angiotensin receptor prevents streptozotocin-induced diabetic nephropathy |
title | Vaccination against type 1 angiotensin receptor prevents streptozotocin-induced diabetic nephropathy |
title_full | Vaccination against type 1 angiotensin receptor prevents streptozotocin-induced diabetic nephropathy |
title_fullStr | Vaccination against type 1 angiotensin receptor prevents streptozotocin-induced diabetic nephropathy |
title_full_unstemmed | Vaccination against type 1 angiotensin receptor prevents streptozotocin-induced diabetic nephropathy |
title_short | Vaccination against type 1 angiotensin receptor prevents streptozotocin-induced diabetic nephropathy |
title_sort | vaccination against type 1 angiotensin receptor prevents streptozotocin-induced diabetic nephropathy |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4762923/ https://www.ncbi.nlm.nih.gov/pubmed/26407577 http://dx.doi.org/10.1007/s00109-015-1343-6 |
work_keys_str_mv | AT dingdan vaccinationagainsttype1angiotensinreceptorpreventsstreptozotocininduceddiabeticnephropathy AT duyimei vaccinationagainsttype1angiotensinreceptorpreventsstreptozotocininduceddiabeticnephropathy AT qiuzhihua vaccinationagainsttype1angiotensinreceptorpreventsstreptozotocininduceddiabeticnephropathy AT yansen vaccinationagainsttype1angiotensinreceptorpreventsstreptozotocininduceddiabeticnephropathy AT chenfen vaccinationagainsttype1angiotensinreceptorpreventsstreptozotocininduceddiabeticnephropathy AT wangmin vaccinationagainsttype1angiotensinreceptorpreventsstreptozotocininduceddiabeticnephropathy AT yangshijun vaccinationagainsttype1angiotensinreceptorpreventsstreptozotocininduceddiabeticnephropathy AT zhouyanzhao vaccinationagainsttype1angiotensinreceptorpreventsstreptozotocininduceddiabeticnephropathy AT huxiajun vaccinationagainsttype1angiotensinreceptorpreventsstreptozotocininduceddiabeticnephropathy AT dengyihuan vaccinationagainsttype1angiotensinreceptorpreventsstreptozotocininduceddiabeticnephropathy AT wangshijia vaccinationagainsttype1angiotensinreceptorpreventsstreptozotocininduceddiabeticnephropathy AT wangliangping vaccinationagainsttype1angiotensinreceptorpreventsstreptozotocininduceddiabeticnephropathy AT zhanghongrong vaccinationagainsttype1angiotensinreceptorpreventsstreptozotocininduceddiabeticnephropathy AT wuhailang vaccinationagainsttype1angiotensinreceptorpreventsstreptozotocininduceddiabeticnephropathy AT yuxian vaccinationagainsttype1angiotensinreceptorpreventsstreptozotocininduceddiabeticnephropathy AT zhouzihua vaccinationagainsttype1angiotensinreceptorpreventsstreptozotocininduceddiabeticnephropathy AT liaoyuhua vaccinationagainsttype1angiotensinreceptorpreventsstreptozotocininduceddiabeticnephropathy AT chenxiao vaccinationagainsttype1angiotensinreceptorpreventsstreptozotocininduceddiabeticnephropathy |